Bresat Cancer Update
Oncology Leader CommentarySpecial FeaturesPrevious Issues

Home: Oncology Leader Commentary: Nancy E. Davidson, MD

Click on the topic below for comments by Dr Nancy E. Davidson to comment on. You will also find links to related articles and clinical trials.

Intergroup study of adjuvant ovarian suppression
Main results of Intergroup adjuvant premenopausal study
Management of node-postive, ER+ premenopausal patients
Ovarian ablation after chemotherapy in patients who continue to menstrate
Harvey study of estrogen receptors
Use of adjuvant tamoxifen
Choice of aromatase inhibitor
Management of metastatic disease in younger women
Combined endocrine therapy in premenopausal patients with metastases
Tamoxifen for patients with DCIS
Psychosocial issue in young breast cancer patients
Risk for recurrence and use of cytotoxic therapy
Use of prognostic factors in invasive breast cancer

Psychosocial issue in young breast cancer patients

Interview with Neil Love, MD from Breast Cancer Update for Medical Oncologists, Program 3 2000

Play Audio Below:

Dr. Love: Another topic I wanted to bring up to you – we were talking about the younger breast cancer patient – can you talk a little bit about some of the psychosocial issues that come up and management of those women compared to the older patients that you run into?

Dr. Davidson: I guess the two biggest issues I run into are those who weren’t ready to finish their families, and so that’s always very trying and particularly if they come to the end of their treatment and they still are premenopausal. Then we often go through a lot of angst about, "Should she get pregnant? When can she get pregnant? What does all this mean? How do we integrate the tamoxifen?" So I think that’s one whole set of issues for them. I guess I haven’t found that they seem to have more symptom problems than older women, for example. I guess probably the pregnancy issue is the biggest thing, Neil. What I see is almost exclusively women who have two kids, a husband, a dog, and a job and they don’t seem to have a lot of free time, as far as I can tell. A lot of them do find it’s the post-treatment period that’s the most difficult for them in terms of coping. I’ve actually started counseling them about that when they finish their therapy – that your spirits may actually take a dive for the next few months more than you might think. You think you’re done – you’re going to feel great – and in fact, a lot of them are actually quite blue afterwards for a couple of months. And, if they’re forewarned, it turns out not to be a big issue. And, I guess, my simple explanation is they’re so busy getting treatment and sort of feeling like they’re fighting their breast cancer. Then, suddenly, they come from a time when they saw all of us all the time to a time when they’re in follow-up and they don’t see many of us very much and they have this sense that: a) maybe they’re not fighting their breast cancer anymore, you know, they’re more vulnerable. b) they’ve been pushed out of the nest or they’ve come out of the nest, and c) they finally had time to think about the fact that they’ve been told they have breast cancer, which is really very scary.

Relevant Articles:

Long-term quality of life in premenopausal women with node-negative localized breast cancer treated with or without adjuvant chemotherapy.
Joly F, Espie M, Marty M, Heron JF, Henry-Amar M. Br J Cancer. 2000 Sep;83(5):577-82.

Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. Ganz PA, Greendale GA, Petersen L, Zibecchi L, Kahn B, Belin TR. J Natl Cancer Inst. 2000 Jul 5;92(13):1054-64.

Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life.
Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE, Belin TR.J Clin Oncol. 2000 Feb;18(4):743-53.

Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B. J Clin Oncol. 1999 Sep;17(9):2659-69.

Proposed agenda for the measurement of quality-of-care outcomes in oncology practice.
Mandelblatt JS, Ganz PA, Kahn KL. J Clin Oncol. 1999 Aug;17(8):2614-22.

Predictors of sexual health in women after a breast cancer diagnosis.
Ganz PA, Desmond KA, Belin TR, Meyerowitz BE, Rowland JH. J Clin Oncol. 1999 Aug;17(8):2371-80.

Quality of life in the first year after breast cancer surgery: rehabilitation needs and patterns of recovery.
Shimozuma K, Ganz PA, Petersen L, Hirji K. Breast Cancer Res Treat. 1999 Jul;56(1):45-57.

Are older breast carcinoma survivors willing to take hormone replacement therapy?
Ganz PA, Greendale GA, Kahn B, O'Leary JF, Desmond KA. Cancer. 1999 Sep 1;86(5):814-20.

Sexuality following breast cancer.
Meyerowitz BE, Desmond KA, Rowland JH, Wyatt GE, Ganz PA. J Sex Marital Ther. 1999 Jul-Sep;25(3):237-50.

Psychosocial concerns and quality of life in breast cancer survivors.
Leedham B, Ganz PA. Cancer Invest. 1999;17(5):342-8.

Quality of life of African-American and white long term breast carcinoma survivors.
Ashing-Giwa K, Ganz PA, Petersen L. Cancer. 1999 Jan 15;85(2):418-26

The quality of life after breast cancer--solving the problem of lymphedema.
Ganz PA. N Engl J Med. 1999 Feb 4;340(5):383-5.

Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors.
Ganz PA, Rowland JH, Meyerowitz BE, Desmond KA. Recent Results Cancer Res. 1998;152:396-411.

Sexual functioning and intimacy in African American and white breast cancer survivors: a descriptive study.
Wyatt GE, Desmond KA, Ganz PA, Rowland JH, Ashing-Giwa K, Meyerowitz BE. Womens Health. 1998 Winter;4(4):385-405.

The prognostic value of quality-of-life scores: preliminary results of an analysis of patients with breast cancer.
Shimozuma K, Sonoo H, Ichihara K, Tanaka K.Surg Today. 2000;30(3):255-61.

Relevant Clinical Trials:

Prospective Study of Potential Factors Affecting Weight in Breast Cancer Patients Receiving Adjuvant Chemotherapy

Top of Page

Home · Contact us
Terms of use and general disclaimer